Leonteq Securities’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$29.3K Buy
+525
New +$28.4K ﹤0.01% 868
2026
Q1
– Sell
-3,993
Closed -$119K – 1484
2025
Q4
$119K Buy
3,993
+1,109
+38% +$36.2K ﹤0.01% 770
2025
Q3
$104K Buy
2,884
+1,546
+116% +$50.9K ﹤0.01% 738
2025
Q2
$48.2K Buy
1,338
+1,211
+954% +$45.1K ﹤0.01% 855
2025
Q1
$5.01K Sell
127
-1,119
-90% -$37.7K ﹤0.01% 1100
2024
Q4
$37.5K Buy
1,246
+596
+92% +$17.1K ﹤0.01% 875
2024
Q3
$15.2K Buy
650
+150
+30% +$3.28K ﹤0.01% 942
2024
Q2
$8.9K Sell
500
-300
-38% -$4.79K ﹤0.01% 995
2024
Q1
$12.2K Buy
+800
New +$12.7K ﹤0.01% 987
2022
Q4
– Sell
-600
Closed -$3.55K – 1359
2022
Q3
$3.55K Hold
600
– – ﹤0.01% 1152
2022
Q2
$2.55K Hold
600
– – ﹤0.01% 1190
2022
Q1
$5.71K Hold
600
– – ﹤0.01% 1157
2021
Q4
$11.4K Buy
+600
New +$15.6K ﹤0.01% 1147
2021
Q3
– Sell
-790
Closed -$30.6K – 1219
2021
Q2
$30.6K Buy
790
+340
+76% +$13.4K ﹤0.01% 894
2021
Q1
$21.7K Buy
+450
New +$21.6K ﹤0.01% 877

Other funds holding TGTX

Leonteq Securities's TGTX Position: Q3 2026 in Review

Leonteq Securities opened a new position in TG Therapeutics (TGTX) in Q3 2026: 525 shares worth $29.3K. The stake represents ﹤0.01% of the portfolio and ranks #868 among its holdings. This is a return to the name: Leonteq Securities previously reported a position in TGTX as recently as Q4 2025.

Leonteq Securities first reported a position in TGTX in Q1 2021 and has held it in 15 quarters since. The position peaked at $119K in Q4 2025. 370 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • Leonteq Securities held 525 shares of TG Therapeutics worth $29.3K as of Q3 2026.
  • TG Therapeutics was a new Leonteq Securities position in Q3 2026.
  • TG Therapeutics made up ﹤0.01% of Leonteq Securities's portfolio in Q3 2026, its #868 holding.
  • Leonteq Securities first reported a position in TG Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • Leonteq Securities's TG Therapeutics position peaked at $119K in Q4 2025.
  • 370 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.